Passivity-Based Inverse Optimal Impulsive Control for Influenza Treatment in the Host

Influenza A virus infections are causes of severe illness resulting in high levels of mortality. Neuraminidase inhibitors such as zanamivir and oseltamivir are used to treat influenza; however, treatment recommendations remain debatable. In this paper, a discrete-time inverse optimal impulsive contr...

Full description

Saved in:
Bibliographic Details
Published in:IEEE transactions on control systems technology 2020-01, Vol.28 (1), p.94-105
Main Authors: Hernandez-Mejia, Gustavo, Alanis, Alma Y., Hernandez-Gonzalez, Miguel, Findeisen, Rolf, Hernandez-Vargas, Esteban A.
Format: Article
Language:English
Subjects:
Clinical trials
Computer simulation
Corrosion inhibitors
Data models
Drugs
Host treatment
impulsive control
infections
Influenza
influenza A
Inhibitors
inverse optimal control
Level (quantity)
Mathematical model
Nickel
Optimization
Passivity
Robust control
Robustness (mathematics)
Schedules
Viruses
Viruses (medical)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Influenza A virus infections are causes of severe illness resulting in high levels of mortality. Neuraminidase inhibitors such as zanamivir and oseltamivir are used to treat influenza; however, treatment recommendations remain debatable. In this paper, a discrete-time inverse optimal impulsive control scheme based on passivation is proposed to address the antiviral treatment scheduling problem. We adapt results regarding stability, passivity, and optimality for the impulsive action. The study is founded on mathematical models whose parameters are adjusted to data from clinical trials where participants were experimentally infected with influenza H1N1 and treated with either zanamivir or oseltamivir. Simulation results show that control-based techniques can reduce the amount of medication while simultaneously reach the efficacy levels of the treatment schedules by the Food and Drug Administration. Monte Carlo simulations disclose the robustness of the proposed control-based techniques.
ISSN:1063-6536
1558-0865
DOI:10.1109/TCST.2019.2892351